Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.14 +0.59 (+0.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,544,382
Open	92.52
Bid (Size)	91.60 (200)
Ask (Size)	93.01 (300)
Prev. Close	91.55
Today's Range	91.94 - 93.10
52wk Range	61.24 - 94.02
Shares Outstanding	N/A
Dividend Yield	1.12%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗

Today 7:41 EST

AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

Via Chartmill

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Via PredictStreet

Performance

YTD	+39.9%	+39.9%
1 Month	+0.7%	+0.7%
3 Month	+21.3%	+21.3%
6 Month	+30.6%	+30.6%
1 Year	+38.3%	+38.3%

More News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

December 22, 2025

From AstraZeneca

Via Business Wire

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

Via Stocktwits

3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗

December 18, 2025

Via The Motley Fool

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

Via Stocktwits

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

December 15, 2025

From AstraZeneca

Via Business Wire

What to Watch With IonQ Stock in 2026 ↗

December 11, 2025

Via The Motley Fool

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

December 04, 2025

From AstraZeneca

Via Business Wire

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

December 02, 2025

From AstraZeneca

Via Business Wire

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

Via Stocktwits

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

November 27, 2025

Via Stocktwits

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Via Investor's Business Daily

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

November 26, 2025

From AstraZeneca

Via Business Wire

AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗

November 25, 2025

Via Chartmill

Why AstraZeneca Stock Bumped Higher Today ↗

November 21, 2025

Via The Motley Fool

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

November 21, 2025

From AstraZeneca

Via Business Wire

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗

November 20, 2025

Via Benzinga

Where Will IonQ Be in 10 Years? ↗

November 20, 2025

Via The Motley Fool

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗

November 17, 2025

Via Investor's Business Daily

IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race

November 14, 2025

Via MarketMinute

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Why AstraZeneca Stock Was a Winner Today ↗

November 10, 2025

Via The Motley Fool

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

Via TokenRing AI

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial ↗

November 10, 2025

Via Benzinga

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 92.14

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 12/23/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.